How do I read and understand my HER2-Positive Breast Cancer pathology report

Understanding Your HER2-Positive Breast Cancer Pathology Report

I'm glad you're taking the time to understand your pathology report—this is an important step in your care. Let me walk you through what you'll typically see and what it means.

What Your Report Should Include

According to NCCN Guidelines for Invasive Breast Cancer, your pathology report should contain several key pieces of information:

1. HER2 Status (The Main Finding for You)

Your report will show one of these HER2 test results:

HER2-Positive (HER2+) means your cancer cells have higher-than-normal amounts of a protein called HER2 (human epidermal growth factor receptor 2). Think of HER2 as a growth signal on the surface of cells—when there's too much of it, it tells cancer cells to grow and divide faster.

The report will likely show this in one of two ways:

• IHC Score (Immunohistochemistry): This measures HER2 receptors directly

  • IHC 3+ = HER2-Positive ✓
  • IHC 2+ = Equivocal (unclear—needs additional testing)
  • IHC 0-1+ = HER2-Negative

• ISH Result (In Situ Hybridization): This counts copies of the HER2 gene

  • HER2/CEP17 ratio ≥2.0 AND average HER2 copy number ≥4.0 signals/cell = HER2-Positive ✓

Why this matters: HER2-positive status opens up specific treatment options. According to NCCN Guidelines, HER2-targeted therapy is a standard treatment approach for HER2+ cancers, using drugs like trastuzumab (Herceptin) and pertuzumab (Perjeta).

2. Hormone Receptor Status (ER and PR)

Your report will also show whether your cancer is hormone receptor-positive or negative:

• ER+ (Estrogen Receptor-Positive): Cancer cells respond to estrogen
• PR+ (Progesterone Receptor-Positive): Cancer cells respond to progesterone
• ER-/PR-: Cancer cells don't respond to these hormones

What this means for you:

• If you're HR+ with HER2+ (also called triple-positive): You'll receive both HER2-targeted therapy AND endocrine therapy (hormone-blocking treatment)
• If you're HR- with HER2+: Treatment focuses on HER2-targeted therapy, typically with chemotherapy

3. Grade and Stage Information

• Grade (1-3): How abnormal the cancer cells look under a microscope. Higher grade = more aggressive
• Stage: How far the cancer has spread (based on tumor size, lymph nodes, and metastasis)
• Histologic type: The specific type of breast cancer (invasive ductal carcinoma, invasive lobular carcinoma, etc.)

4. Other Important Details

• Tumor size: Measured in centimeters
• Lymph node involvement: Whether cancer reached nearby lymph nodes
• Margins: Whether cancer cells were found at the edges of the removed tissue
• Ki-67 index: A measure of how fast cells are dividing (higher = faster growth)

---

How to Read the Numbers and Results

Example of what you might see:

| Finding | What It Means | |---------|---------------| | "HER2 IHC 3+" | Strong HER2 overexpression—clearly HER2-positive | | "HER2/CEP17 ratio 2.5" | Gene copy number shows HER2 amplification | | "ER 85%, PR 70%" | High percentage of cells with hormone receptors | | "Grade 2, Stage IIB" | Moderately aggressive cancer, intermediate stage | | "Negative margins" | Good news—cancer cells weren't at the edges |

---

Questions to Ask Your Oncologist

Since you have HER2-positive breast cancer, here are specific questions that will help you understand your treatment options:

1. "Based on my HER2 status and hormone receptor status, what treatment approach do you recommend—and why?"

2. "Will I receive HER2-targeted therapy? If so, which drugs (trastuzumab, pertuzumab, or others)?"

3. "Since I'm HER2-positive, will I need chemotherapy before or after surgery, or both?"

4. "How long will HER2-targeted therapy last, and what are the side effects I should expect?"

5. "Are there any other biomarkers in my report (like Ki-67 or specific genetic mutations) that affect my treatment plan?"

6. "What does my grade and stage tell us about my prognosis and treatment intensity?"

---

Key Takeaway

Your HER2-positive status is actually informative and actionable—it means your cancer responds to specific targeted therapies that have been proven effective. According to NCCN Guidelines, HER2-targeted therapy combined with appropriate chemotherapy and/or hormone therapy (depending on your hormone receptor status) is the standard approach for HER2+ breast cancer.

The more you understand your pathology report, the better you can participate in decisions about your care with your oncology team.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.